BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 17761520)

  • 1. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
    Liu Q; Zhao X; Frissora F; Ma Y; Santhanam R; Jarjoura D; Lehman A; Perrotti D; Chen CS; Dalton JT; Muthusamy N; Byrd JC
    Blood; 2008 Jan; 111(1):275-84. PubMed ID: 17761520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells.
    Wallington-Beddoe CT; Hewson J; Bradstock KF; Bendall LJ
    Autophagy; 2011 Jul; 7(7):707-15. PubMed ID: 21460633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
    Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
    Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
    Mani R; Mao Y; Frissora FW; Chiang CL; Wang J; Zhao Y; Wu Y; Yu B; Yan R; Mo X; Yu L; Flynn J; Jones J; Andritsos L; Baskar S; Rader C; Phelps MA; Chen CS; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Leukemia; 2015 Feb; 29(2):346-55. PubMed ID: 24947019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft.
    Ubai T; Azuma H; Kotake Y; Inamoto T; Takahara K; Ito Y; Kiyama S; Sakamoto T; Horie S; Muto S; Takahara S; Otsuki Y; Katsuoka Y
    Anticancer Res; 2007; 27(1A):75-88. PubMed ID: 17352219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.
    Zonta F; Pagano MA; Trentin L; Tibaldi E; Frezzato F; Trimarco V; Facco M; Zagotto G; Pavan V; Ribaudo G; Bordin L; Semenzato G; Brunati AM
    Blood; 2015 Jun; 125(24):3747-55. PubMed ID: 25931585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
    Lu Z; Wang J; Zheng T; Liang Y; Yin D; Song R; Pei T; Pan S; Jiang H; Liu L
    BMC Cancer; 2014 Oct; 14():783. PubMed ID: 25344679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.
    Chen L; Luo LF; Lu J; Li L; Liu YF; Wang J; Liu H; Song H; Jiang H; Chen SJ; Luo C; Li KK
    PLoS One; 2014; 9(7):e103033. PubMed ID: 25050888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720.
    Nagahara Y; Matsuoka Y; Saito K; Ikekita M; Higuchi S; Shinomiya T
    Jpn J Cancer Res; 2001 Jun; 92(6):680-7. PubMed ID: 11429058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
    Lucas DM; Edwards RB; Lozanski G; West DA; Shin JD; Vargo MA; Davis ME; Rozewski DM; Johnson AJ; Su BN; Goettl VM; Heerema NA; Lin TS; Lehman A; Zhang X; Jarjoura D; Newman DJ; Byrd JC; Kinghorn AD; Grever MR
    Blood; 2009 May; 113(19):4656-66. PubMed ID: 19190247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
    Marzo I; Pérez-Galán P; Giraldo P; López-Royuela N; Gómez-Benito M; Larrad L; Lasierra P; Rubio-Félix D; Anel A; Naval J
    Leukemia; 2004 Oct; 18(10):1599-604. PubMed ID: 15356656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria.
    Nagahara Y; Ikekita M; Shinomiya T
    J Immunol; 2000 Sep; 165(6):3250-9. PubMed ID: 10975841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2.
    Nagahara Y; Ikekita M; Shinomiya T
    Br J Pharmacol; 2002 Dec; 137(7):953-62. PubMed ID: 12429567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia.
    Wallington-Beddoe CT; Don AS; Hewson J; Qiao Q; Papa RA; Lock RB; Bradstock KF; Bendall LJ
    PLoS One; 2012; 7(5):e36429. PubMed ID: 22570713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.
    Liu Q; Alinari L; Chen CS; Yan F; Dalton JT; Lapalombella R; Zhang X; Mani R; Lin T; Byrd JC; Baiocchi RA; Muthusamy N
    Clin Cancer Res; 2010 Jun; 16(12):3182-92. PubMed ID: 20460491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
    Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
    Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells.
    Matsuoka Y; Nagahara Y; Ikekita M; Shinomiya T
    Br J Pharmacol; 2003 Apr; 138(7):1303-12. PubMed ID: 12711631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
    Estella-Hermoso de Mendoza A; Castello-Cros R; Imbuluzqueta E; Cirauqui C; Pippa R; Odero MD; Blanco-Prieto MJ
    J Biomed Nanotechnol; 2015 Apr; 11(4):691-701. PubMed ID: 26310075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
    Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
    Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
    Battle TE; Arbiser J; Frank DA
    Blood; 2005 Jul; 106(2):690-7. PubMed ID: 15802533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.